📄 medicine

Efficacy Evaluation and Pharmacological Mechanism Exploration of Polyporus umbellatus (Pers.) Fries in Hepatitis E Virus Treatment: A Combined Study of Meta-Analysis, Network Pharmacology, and Molecular Docking

This study integrates meta-analysis, network pharmacology, and molecular docking to demonstrate that *Polyporus umbellatus* effectively alleviates hepatitis E virus-induced liver damage by modulating specific bioactive compounds, molecular targets, and signaling pathways, thereby providing a scientific basis for its clinical translation.

Original authors: Zhenwen He, Dingyu Liu, Qin Luo, Baoling Liu, Dongqi Chen, Hua Xiang, Xiaohu Wang, Gang Wang, Yuan Huang, Jing C Chen, Rujian Cai

Published 2026-06-29

📖 5 min read🧠 Deep dive

CC BY 4.0

Original authors: Zhenwen He, Dingyu Liu, Qin Luo, Baoling Liu, Dongqi Chen, Hua Xiang, Xiaohu Wang, Gang Wang, Yuan Huang, Jing C Chen, Rujian Cai

Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). ✨ This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer

The Big Picture: A Three-Part Detective Story

Imagine a team of scientists trying to solve a mystery: Can a specific mushroom called Polyporus umbellatus (known in traditional medicine as "Zhuling") actually help heal the liver when it's attacked by the Hepatitis E virus?

Since the virus is tricky and there aren't many "magic bullet" drugs for it yet, the researchers didn't just guess. They used a three-step detective strategy to find the answer:

The Evidence Collector (Meta-Analysis): They gathered all existing human studies to see if the mushroom worked in real life.
The Map Maker (Network Pharmacology): They used computers to draw a map of how the mushroom's chemicals interact with the human body.
The Locksmith (Molecular Docking): They simulated how the mushroom's chemicals fit into the body's "locks" (proteins) to see if they fit tightly.

Step 1: The Evidence Collector (Did it work in people?)

The researchers went through a massive library of medical records (databases like PubMed and CNKI) looking for clinical trials. They found 10 studies involving over 650 patients with viral hepatitis.

The Analogy: Imagine 10 different doctors treating patients with a broken leg. Some gave just a cast (standard care), while others gave a cast plus a special healing powder (the mushroom).
The Result: The "mushroom group" healed significantly better.
- Liver Damage went down: The "broken leg" indicators (enzymes like ALT and AST, and bilirubin) dropped sharply.
- Liver Strength went up: The "muscle" indicator (Albumin) increased.
- Overall Success: Patients treated with the mushroom were 3.5 times more likely to see a total improvement compared to those who didn't take it.

The Verdict: The mushroom isn't just a placebo; it genuinely helps the liver recover from viral attacks.

Step 2: The Map Maker (How does it work?)

Now that they knew it worked, they asked: How? Since the mushroom is a complex mix of chemicals, they couldn't test every single one by hand. Instead, they used Network Pharmacology, which is like using a GPS to trace a route through a giant city.

The Ingredients: They filtered the mushroom's chemical soup and found 11 "active agents" (mostly steroid-like compounds and polysaccharides) that are strong enough to survive digestion and enter the bloodstream.
The Targets: They found 124 specific "targets" in the human body that these agents might hit.
The Intersection: By overlapping the mushroom's targets with the Hepatitis E virus's targets, they found 12 "Super Targets" (like MAP2K1, ESR1, and PIK3R1) that are crucial for fighting the virus.

The Analogy: Think of the Hepatitis E virus as a burglar trying to break into a house (the liver). The mushroom sends out 11 different security guards. These guards don't just chase the burglar; they go to 12 specific doors and windows (the targets) to lock them up, cut off the burglar's power supply, and call the police (the immune system).

The Pathways: The study found these guards work through several "highways" in the body, including:

Estrogen Signaling: Helping regulate cell growth.
T-Cell Signaling: Boosting the immune system's soldiers.
Proteoglycans in Cancer: A pathway that helps stop uncontrolled cell growth (which is bad for the liver).

Step 3: The Locksmith (Do the keys fit?)

Finally, the researchers used a computer simulation called Molecular Docking to see if the mushroom's chemicals actually fit into the "locks" (the 12 Super Targets) they identified.

The Analogy: Imagine the body's targets are locks, and the mushroom's chemicals are keys. You can have a key that looks like it fits, but if it's the wrong shape, it won't turn.
The Result: The simulation showed that the top keys (specifically Cerevisterol and (22E, 24R)-ergosta-7,22-dien-3-one) fit perfectly and tightly into the locks.
The Score: In the world of chemistry, a "binding energy" score of less than -5.0 is considered a "good fit." These mushroom keys scored between -7.1 and -9.3, meaning they lock in very securely.

The Verdict: The computer confirms that the mushroom's active ingredients physically stick to the specific parts of the body needed to fight the virus.

The Catch (Limitations)

The authors are honest about what they didn't do.

The "Virtual" Lab: The "Map Making" and "Locksmith" steps happened entirely inside a computer. They haven't yet tested these specific chemical keys in a real petri dish or a living animal model for Hepatitis E.
Why? It's very hard to grow the Hepatitis E virus in a lab (it's like trying to grow a specific type of rare orchid that only blooms in a storm). Because of this, they couldn't do the final "real-world" lab test to prove the computer predictions are 100% true yet.

Summary

This paper is a proof-of-concept.

Real-world data shows the mushroom helps liver patients.
Computer maps show which chemicals in the mushroom are likely doing the work.
Computer simulations show those chemicals fit tightly into the body's defense mechanisms.

The study concludes that Polyporus umbellatus is a promising natural tool for fighting Hepatitis E, working through a "team effort" of multiple chemicals hitting multiple targets, but more real-world lab experiments are needed to confirm exactly how it stops the virus.

Technical Summary: Efficacy Evaluation and Pharmacological Mechanism Exploration of Polyporus umbellatus (Pers.) Fries in Hepatitis E Virus Treatment

Problem Statement
Hepatitis E virus (HEV) remains a significant cause of acute hepatitis and mortality, particularly among pregnant women, the elderly, and immunocompromised individuals. Currently, no direct-acting antiviral agents are approved for clinical use against HEV; existing treatments like ribavirin and interferon-α have limited efficacy and safety concerns, especially in pregnant populations. While Polyporus umbellatus (Pers.) Fries (Zhuling) is a well-established traditional Chinese medicine (TCM) remedy for liver conditions with documented hepatoprotective, anti-inflammatory, and anti-fibrotic properties, its specific therapeutic efficacy against HEV and the underlying molecular mechanisms remain poorly understood and undocumented in existing literature.

Methodology
This study employed a tripartite approach combining clinical evidence synthesis with computational systems biology:

Meta-Analysis: A systematic review and meta-analysis were conducted following PRISMA guidelines and registered in PROSPERO (ID: CRD420251183539). Ten randomized controlled trials (RCTs) published between 2000 and 2025, involving over 650 participants with viral hepatitis, were analyzed. Data were extracted from CNKI, Wanfang, Web of Science, SpringerLink, PubMed, and ScienceDirect. Outcomes included overall effectiveness and liver function markers (ALT, AST, TBIL, ALB). Heterogeneity was assessed using $I^2$ statistics, and evidence quality was graded using the GRADE framework.
Network Pharmacology: Active bioactive compounds of P. umbellatus were screened from the TCMSP database using criteria of oral bioavailability (OB) $\ge$ 30% and drug-likeness (DL) $\ge$ 0.18. Targets for these compounds were predicted via PharmMapper and SwissTargetPrediction. HEV-related targets were retrieved from GeneCards, OMIM, and TTD. Intersection analysis identified potential therapeutic targets, which were further analyzed via Protein-Protein Interaction (PPI) networks (STRING database) and topological screening in Cytoscape. Functional enrichment (GO and KEGG) was performed using DAVID.
Molecular Docking: The top five key targets identified through pathway enrichment were docked with the core bioactive compounds using AutoDockTools. Binding affinity was evaluated to validate the stability of ligand-target interactions, with a threshold of $\le$ -5.0 kJ/mol considered indicative of good binding activity.

Key Results

Clinical Efficacy (Meta-Analysis): The meta-analysis demonstrated that P. umbellatus supplementation significantly improved overall treatment efficacy compared to conventional therapy (OR = 3.48, 95% CI: 2.17–5.59, $p < 0.00001$ ). It significantly reduced liver damage markers: Alanine Aminotransferase (ALT) (SMD = 1.18), Aspartate Aminotransferase (AST) (SMD = 1.23), and Total Bilirubin (TBIL) (SMD = 1.01), while significantly increasing Albumin (ALB) levels (SMD = 0.62). While heterogeneity was substantial for ALT, AST, and TBIL ( $I^2 > 85\%$ ), it was low for overall efficacy and ALB. GRADE assessment rated the evidence for overall efficacy and ALB as "high certainty," and for ALT, AST, and TBIL as "moderate certainty."
Active Compounds and Targets: Eleven active components were identified, primarily sterols and triterpenoids (e.g., Cerevisterol, (22E, 24R)-ergosta-7,22-dien-3-one, Polyporusterone E). The study identified 124 intersecting targets between P. umbellatus compounds and HEV.
Mechanistic Pathways: PPI network analysis highlighted 12 core targets, including CYP17A1, ESR1, MAPK14, PIK3R1, and PRKACA. GO and KEGG enrichment analyses revealed that P. umbellatus acts through multiple pathways, including endocrine resistance, proteoglycans in cancer, prolactin signaling, estrogen signaling, and T-cell receptor signaling. These pathways are implicated in immune regulation, inflammation control, and hepatocellular homeostasis.
Molecular Docking: All key bioactive compounds exhibited binding energies $\le$ -5.0 kJ/mol with the core targets. Cerevisterol and (22E, 24R)-ergosta-7,22-dien-3-one showed the strongest binding affinities (e.g., -9.3 kJ/mol with MAP2K1), confirming their potential as the primary mediators of the anti-HEV effect.

Significance and Claims
The authors claim that this study provides the first systematic clarification of the therapeutic efficacy and molecular mechanisms of P. umbellatus against HEV. By integrating clinical data with computational predictions, the study establishes a "multi-component, multi-target, multi-pathway" mechanism for the fungus's hepatoprotective activity. The findings suggest that P. umbellatus alleviates HEV-induced liver damage by modulating immune responses, reducing inflammation, and promoting liver repair through specific signaling pathways. The study posits that these results offer a theoretical basis for the clinical translation of P. umbellatus and the development of novel natural antiviral drugs for hepatitis E.

Limitations Acknowledged by the Authors
The paper explicitly notes several constraints:

The meta-analysis included a limited number of studies (10), and publication bias cannot be entirely ruled out.
Network pharmacology relies on database information which may be incomplete or outdated.
The proposed targets and pathways are based on in silico predictions and lack experimental validation. The authors cite the current lack of ideal in vitro and in vivo HEV infection models (due to difficulties in propagating wild-type HEV in cell cultures) as a primary reason for the inability to validate these findings experimentally at this stage.
The specific synergistic effects of the multiple components within P. umbellatus require further clarification.